Sunnyvale, California., November 17, 2022 /PRNewswire/ — EBR Systems, Inc. (ASX: “EWC”, “EBR Systems”or the “Company”), developer of the world’s only wireless heart failure pacemaker system, is pleased to announce that WiSE® Technology will be at the 15thth Asia Pacific Heart Rhythm Society (APHRS) Scientific Meeting in Singapore from the 18thth until the 20thth November.
The APHRS is a leading not-for-profit organization representing medical, allied health and scientific professionals specializing in cardiac arrhythmias Asia Pacific Region. The annual conference is a premier event with industry workshops and a core scientific program delivered by international and regional speakers.
Five abstracts with WiSE® were accepted for presentations, underscoring the technology’s position at the forefront of innovation in the cardiac rhythm management landscape. Abstracts with WiSE® at the APHRS Scientific Session include the following:
- Performs cardiac resynchronization with WiSE® – CRT leadless pacing leads to greater QRS shortening than traditional resynchronization? – DR Simon James (James Cook University Hospital, UK)
- Feasibility of a fully leadless CRT with leadless pacemaker and leadless LV endocardial pacing system -Prof Pascal Defaye (University Hospital Grenoble Alpes, France)
- Leadless Left Bundle Branch Area Pacing: A Proof of Concept – DR Markus Eliot (St Thomas Hospital, UK)
- The effect of lead position on battery life during leadless LV endocardial pacing – DR Markus Eliot (St Thomas Hospital, UK)
- The first completely lead-free CRT system in the USA – DR Dinesh Sharma (NCH Heart Institute, United States of America)
John McCutcheonPresident & Chief Executive Officer of EBR Systems said:
“We are excited about our WiSE® System continues to be featured at leading conferences around the world. The abstracts presented at this scientific session reinforce the body of data that supports WiSE® while also introducing our technology to a broad audience, including industry partners and the broader scientific community.”
About EBR systems (ASX: EBR)
Based in Silicon Valley, EBR Systems (ASX:EBR) is dedicated to providing superior treatment for cardiac arrhythmia by providing more physiologically effective pacing from wireless cardiac pacemakers. Patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for pacemaker leads, which historically have been the leading cause of complications and reliability issues in treating cardiac arrhythmias. The first product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring cardiac resynchronization therapy (CRT). Future products may address wireless endocardial pacing for bradycardia and other non-cardiac indications.
The WiSE® technology from EBR Systems
EBR Systems’ WiSE technology is the world’s only wireless, endocardial (inside the heart) pacing system in clinical use for pacing the left ventricle of the heart. This has long been a goal of pacemaker manufacturers because internal stimulation of the left ventricle is believed to be a potentially superior, more anatomically correct pacing site. WiSE technology enables heart stimulation of the left ventricle with a novel heart implant that is about the size of a large grain of rice. The need for a pacing wire on the outside of the heart’s left ventricle—and the problems associated with it—may be eliminated. WiSE is a test device and is not currently for sale in the United States.
SOURCE EWC Systems